Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation

Plain-language guide to PMID 16765148 (2006): open-label randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 16765148
Journal: Clinical pharmacology and therapeutics
Year: 2006
Study type: Randomized Controlled Trial
Authors: Lerman C et al. (7 authors)
DOI: 10.1016/j.clpt.2006.02.006

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Nicotine is metabolized to cotinine, and cotinine is metabolized to 3'-hydroxycotinine (3-HC) by the liver enzyme cytochrome P450 (CYP) 2A6.

More rapid metabolism of nicotine may result in lower nicotine blood levels from nicotine replacement products and poorer smoking cessation outcomes.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

By use of an open-label design, 480 treatment-seeking smokers were randomly assigned to 8 weeks of transdermal nicotine or nicotine nasal spray use, plus behavioral group counseling.

Assessments included demographics, smoking history, body mass index, and plasma nicotine, cotinine, and 3-HC concentrations, as well as CYP2A6 genotypes.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.

Smoking cessation was biochemically verified at the end of treatment and at 6-month follow-up.

What Was Measured

More rapid metabolism of nicotine may result in lower nicotine blood levels from nicotine replacement products and poorer smoking cessation outcomes.

Topics PubMed links to this paper include Administration, Cutaneous, Administration, Inhalation, Cotinine, Liver, Nicotine and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized and open-label study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.